{"store":{"baseInfo":{"podcastTitle":"The Lancet Psychiatry in conversation with","slug":"lancetpsychiatry","podcastDescription":"Sophia Davis, Senior Editor at The Lancet Psychiatry, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from premature mortality in people with mental illness to cranial electrostimulation therapy for depression, the importance of first-person stories to psychological therapy for sleep problems in young people at risk of psychosis, and more.","podcastLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/22224358/or39zx64e5dzgd0muxelyq7gqw98.jpg","podcastShareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/22224358/or39zx64e5dzgd0muxelyq7gqw98_1200x628.jpg?s=19a1283b86e0596e70c18bb078890a24&e=jpg","podcastUrl":"https://lancetpsychiatry.podbean.com","podcastCanSearched":true,"feedUrl":"https://feed.podbean.com/lancetpsychiatry/feed.xml","theme":"elegant","podcastDeepLink":"https://www.podbean.com/pw/pbblog-zwc3f-1531de6?from=usersite","removePodbeanBranding":"no","brandingLogo":null,"timeZone":{"timeZoneId":29,"gmtAdjustment":"GMT+00:00","useDaylightTime":0,"value":0,"text":"(GMT+00:00) Casablanca, Monrovia, Reykjavik","daylightStartTime":"Second Sunday Of March +2 Hours","daylightEndTime":"First Sunday Of November +2 Hours","timezone":null},"podcastDownloads":null,"totalEpisodes":43,"showComments":true,"iOSAppDownloadLink":null,"customizeCssUrl":null,"androidAppDownloadLink":null,"showPostShare":false,"showLike":false,"author":"The Lancet Group","enableEngagementStats":true,"shareEmbedLink":"https://admin5.podbean.com/embed.html?id=pbblog-zwc3f-1531de6-playlist","language":"en","sensitivitySessionExpireTime":3600,"podcastApps":[{"name":"Podbean App","link":"https://www.podbean.com/pw/pbblog-zwc3f-1531de6?from=usersite","image":"https://pbcdn1.podbean.com/fs1/site/images/admin5/podbean-app.png","title":null}],"components":{"base":[{"id":"MainStyle","val":"light"},{"id":"Font","val":"Geometric Humanist"},{"id":"SecondaryFont","val":"Geometric Humanist"},{"id":"PlayerColor","val":"#428200"},{"id":"PlayerStyle","val":"player1"},{"id":"PlayerWave","val":"show"},{"id":"Favicon","val":null},{"id":"CookiesNotice","val":"hide"},{"id":"CookiesNoticeContent","val":"

Cookies Notice

This website uses cookies to improve your experience while you navigate through the website. By using our website you agree to our use of cookies.

"},{"id":"EpisodePageListenOn","val":"hide"},{"id":"EpisodePageCustomizeComponent","val":"hide"}],"home-header":[{"id":"HomeHeaderTextColor","val":"#000000"},{"id":"HomeHeaderBackgroundColor","val":"#ffffff"}],"page-header":[{"id":"PageHeaderTextColor","val":"#ffffff"},{"id":"PageHeaderBackgroundColor","val":"#868686"}],"episode-list":[{"id":"EpisodeListType","val":"grid"},{"id":"EpisodesPerPage","val":10},{"id":"EpisodeStats","val":"show"}],"navigation":[{"id":"NavigationFontColor","val":"#000000"},{"id":"NavigationBackgroundColor","val":"#e9e9e9"},{"id":"NavigationSearch","val":"show"},{"id":"NavigationLinks","val":[{"id":"Home","type":"Link","value":"/","text":"Home","subitems":[]},{"id":"Subscribe","type":"Link","value":"https://www.podbean.com/site/podcatcher/index/blog/7GRaxmfL1Hyj","text":"Subscribe","subitems":[]},{"id":"Profile","type":"Link","value":"https://www.podbean.com/user-8R92r2F2NIOG","text":"Profile","subitems":[]}]}],"footer":[{"id":"FooterType","val":"Footer2"},{"id":"FooterFontColor","val":"#ffffff"},{"id":"FooterBackgroundColor","val":"#000000"},{"id":"FooterCopyright","val":"© 2026 The Lancet Group"},{"id":"SocialMediaLinks","val":{"facebook_username":"","twitter_username":"","instagram_username":"","youtube_username":"","linkedin_username":""}}],"customize-container1":[],"customize-container2":[]},"allLinks":[],"mainStylesDefaultSettings":null,"defaultCustomizeComponents":null,"scripts":[],"metas":null,"appConfig":{"package":"com.podbean.app.generic","app_store_id":1484287462,"app_name":"Podbean Biz Podcast App","scheme":"enterprise-podbean-com"},"customizeCss":null,"canEditCss":null,"enableJsCodeInCustomizeContent":false,"enabledIframeCodeInCustomizeContent":true,"sectionMaxCount":10,"enableEditorLink":true,"enableEditCookiesNotice":true,"siteRedirectToFeed":false,"podcatcherRssUrl":null,"showFeed":true,"showTopBar":true,"enableWebSiteLike":false,"organizationName":"The Lancet Group","organizationPageLink":"https://www.podbean.com/podcast-network/thelancetgroup"},"backToListUrl":"/","tinymceLoaded":false,"listEpisodes":[],"userLikedEpisodes":[],"userLikeCheckedEpisodes":[],"topBarIframeLoaded":false,"listTotalCount":0,"listTotalPage":0,"listPage":0,"listType":"all","listValue":"","listName":"","pageLoading":false,"apiBaseUrl":"https://lancetpsychiatry.podbean.com","apiV2BaseUrl":"","apiCommonParams":{"t":"6a06b673","clientSignature":"94277944cf0aa59a372d32805bbad160","u":null,"customizing":null},"apiCommonHeaders":{},"comments":[],"commentsTotalCount":0,"commentsTotalPage":0,"commentsPage":1,"commentEpisodeId":"pb27827103-43n5c","episode":{"id":"pb27827103","idTag":"43n5c","title":"Mikkel Højlund on antipsychotics polypharmacy","logo":"https://pbcdn1.podbean.com/imglogo/image-logo/22224358/or39zx64e5dzgd0muxelyq7gqw98_300x300.jpg","shareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/22224358/or39zx64e5dzgd0muxelyq7gqw98_1200x628.jpg?s=19a1283b86e0596e70c18bb078890a24&e=jpg","largeLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/22224358/or39zx64e5dzgd0muxelyq7gqw98.jpg","previewContent":null,"content":"

Sophia Davis talks to Mikkel Højlund about research into the prevalence and outcomes of antipsychotics polypharmacy.

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

","publishTimestamp":1731452400,"duration":1275,"mediaUrl":"https://mcdn.podbean.com/mf/web/d1rurx1alfmyz1nq/1391365_episodes_16065397-mikkel-hojlund-on-antipsychotics-polypharmacy.mp3","mediaType":"audio/mpeg","shareLink":"https://admin5.podbean.com/embed.html?id=pb-43n5c-1a89b9f","likedCount":0,"deepLink":"https://www.podbean.com/ew/pb-43n5c-1a89b9f","transcriptUrl":null,"permalink":"/e/mikkel-h%c3%b8jlund-on-antipsychotics-polypharmacy/","downloadLink":"https://www.podbean.com/media/share/pb-43n5c-1a89b9f?download=1","fallbackResource":null,"fallbackResourceMimetype":null,"downloadCount":47,"status":"publish","hasMoreContent":false,"chaptersUrl":null,"explicit":false},"episodeShareLink":null,"deepLink":"https://www.podbean.com/ew/pb-43n5c-1a89b9f","playlist":{"episodes":[],"current":0,"start":0,"stop":0,"playing":true,"playerLoading":true,"playbackRate":1,"playbackRateIndex":1,"volume":1},"toasts":[],"confirm":null,"customizeEditorFormZIndex":999,"lastRequestTime":null,"validateChangesOnBeforeunload":true,"windowWidth":1000,"VITE_FS1_CDN_URL_PREFIX":"https://pbcdn1.podbean.com/fs1","reloadStats":false,"userIdEncrypted":null,"userProfilePicture":null,"username":null,"isVerified":false,"loadUserInfo":false,"loginUrl":"https://www.podbean.com/site/user/login?return=https%253A%252F%252Flancetpsychiatry.podbean.com%252Fe%252Fmikkel-h%2525c3%2525b8jlund-on-antipsychotics-polypharmacy%252F&rts=6ca761a43538880b6036351fc2ae70e9172e8eb8","recaptchaV3Loaded":false,"recaptchaV2Loaded":false,"likesLoaded":false,"commentLikeMap":{},"commentOffset":0,"widgetCommentsLoaded":false},"episode":{"id":"pb27827103","idTag":"43n5c","title":"Mikkel Højlund on antipsychotics polypharmacy","logo":"https://pbcdn1.podbean.com/imglogo/image-logo/22224358/or39zx64e5dzgd0muxelyq7gqw98_300x300.jpg","shareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/22224358/or39zx64e5dzgd0muxelyq7gqw98_1200x628.jpg?s=19a1283b86e0596e70c18bb078890a24&e=jpg","largeLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/22224358/or39zx64e5dzgd0muxelyq7gqw98.jpg","previewContent":null,"content":"

Sophia Davis talks to Mikkel Højlund about research into the prevalence and outcomes of antipsychotics polypharmacy.